Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on May 7, 2026, and May 11, 2026, for Odyssey Therapeutics, Inc. (ODTX). The filing documents the company's Initial Public Offering (IPO) and a concurrent private placement financing. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Key Financial Metrics and Transaction Details
- Private Placement: The Company sold 1,388,889 shares of Common Stock to TPG LSI Rise Orazio II, L.P. at a price of $18.00 per share.
- Transaction Value: The aggregate purchase price for the private placement was approximately $25.0 million (1,388,889 shares x $18.00).
- Placement Fees: The Company agreed to pay placement agents a fee equal to 7.0% of the total purchase price.
- Financial Statements: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a transactional report regarding equity issuance and corporate governance changes.
Material Changes
The primary material change is the transition from a private to a public company via the IPO and the concurrent private placement. Additionally, the Company amended and restated its Certificate of Incorporation and Bylaws effective immediately prior to the closing of the IPO on May 11, 2026.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future performance, or specific risk factors beyond standard legal disclaimers regarding the Share Purchase Agreement. The agreement includes customary representations and warranties. The shares issued in the private placement were sold pursuant to Section 4(a)(2) of the Securities Act of 1933 and are not registered, though they are treated as registrable securities under an Investor Rights Agreement.
Investor Verification Checklist
- Verify the total IPO proceeds and the final share count post-IPO in the Company's Form S-1 or Form 424B5.
- Review the full text of the Share Purchase Agreement (Exhibit 10.1) for specific covenants and registration rights thresholds.
- Confirm the exact amount of placement agent fees deducted from the gross proceeds.
- Examine the Amended and Restated Certificate of Incorporation (Exhibit 3.1) for any anti-takeover provisions or changes to authorized share capital.
- Check subsequent filings for the actual cash balance and burn rate following the IPO closing.